Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

Share Price is delayed by 15 minutes
Get Live Data
25.75    0.00 (0.00%)
Bid:
25.50
Ask:
26.00
Spread: 0.50 (1.961%)
Market Cap: £129.66m
DUKE Live PriceLast checked at - London Stock Exchange

Intraday Duke Capital Share Chart

Trading Update

11 Apr 2022 07:00

RNS Number : 8761H
Duke Royalty Limited
11 April 2022
 

11 April 2022

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Trading Update

 

Duke Royalty, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and North America, is pleased to provide the following trading update for its fourth financial quarter ended 31 March 2022 ("Q4 FY22"), and to provide guidance on trading for the first quarter of the Company's 2023 financial year, ending 30 June 2022 ("Q1 FY23").

Financial Highlights:

Q4 FY22 represented a record quarter of cash generation in the Company's five-year operating history, both in terms of total cash revenue* and normalised cash revenue**  Total cash revenue was £6.7 million, representing a 37% increase over the previous record quarterly flows in Q2 FY22 of £4.9 million Normalised cash revenue totalled £4.7 million, an increase of 21% on the previous quarter and an 88% increase over Q4 FY21 Following the Company's £5.3 million follow-on investment into Miriad Products ("Miriad") in December 2021, Miriad completed its shareholder restructure in Q4 FY22, realising £1.9 million of cash proceeds to Duke whilst still retaining its 30% equity stake in the business Duke Royalty's last four quarters of Normalised Cash Revenue and Total Cash Revenue are as follows: 

-

Normalised Cash Revenue**

Total Cash Revenue*

Q1 FY22

£2.9 million

£2.9 million

Q2 FY22

£3.3 million

£4.9 million

Q3 FY22

£3.9 million

£3.9 million

Q4 FY22

£4.7 million

£6.7 million

 

* Total cash revenue is monthly cash distributions from Duke's royalty partners plus cash gains received from the sales of equity assets and redemption premiums

** Normalised cash revenue excludes redemption premium receipts and cash gains from equity sales

 

Based on current trading, Duke expects Q1 FY23 normalised cash revenue to be £5.0 million 

Capital Deployments:

During Q4 FY22, Duke committed a further £13.3m of investment to support the "buy and build" strategies of four of its current royalty partners. This was made up of five separate follow-on transactions as follows: 

 -

Two investments into InTec Business Solutions Limited of £2.45 million in January and £1.65 million in February to finance the acquisitions of Provident Technology Limited, Firefly Enterprises Limited and Opal IT Limited, respectively

 -

A £1.5 million investment into Lynx Equity (UK) Ltd to facilitate their acquisition of Obel-P Automation A/S

 -

A £1.55 million investment into Tristone Healthcare Limited to finance its acquisition of Seaside Care Homes Limited

 -

A CA$10.3 million (£6.2 million) investment into Creō-Tech Industrial Group Inc, facilitating the purchase of California-based MD Stainless Services

 Other Q4 Highlights

A second consecutive quarterly dividend rise, increasing 17% from 0.60 pence per quarter to 0.70 pence Drew down the £20 million accordion facility with Honeycomb Investment Trust, unlocking additional liquidity Cash receipt of €4 million from the early repayment of the 2nd tranche of deferred consideration relating to the sale of Duke's three European river cruise vessels. This amount had originally been due for repayment by 30 September 2022. Currently only €2.6 million remains outstanding and due for repayment on or before 30 June 2023 

Neil Johnson, CEO of Duke Royalty, said:

"It is pleasing to report that normalised cash revenue has continued to grow, with Q4 FY22 representing the sixth consecutive quarterly cash revenue increase since the initial impact of Covid. Given Duke's largely fixed cost base, the recent acceleration in deployments has led to a material increase in cashflow per share and we are delighted to be able to share this operational leverage with our shareholders through increasing the quarterly dividend which has risen 27% in the last year.

"We continue to see a strong pipeline of royalty opportunities to service both existing and new companies. Despite the macroeconomic and geopolitical headwinds, our portfolio as a whole continues to perform well. The resilience demonstrated is a benefit of our exposure to a range of underlying companies across diverse geographies and sectors."

***ENDS***

 

For further information, please visit www.dukeroyalty.com or contact:

 

 

Duke Royalty Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

 

+44 (0) 1481 730 613

Cenkos Securities plc 
(Nominated Adviser
and Joint Broker)
 
Stephen Keys / Callum Davidson / Michael Johnson

 

+44 (0) 207 397 8900

 

Canaccord Genuity

(Joint Broker)

 

Adam James / Georgina McCooke

 

 

+44 (0) 207 523 8000

SEC Newgate (PR)

Elisabeth Cowell / Richard Bicknell / Max Richardson

 

+44 (0) 20 3757 6882 dukeroyalty@secnewgate.co.uk

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLTSIIILIF
Date   Source Headline
28th May 20267:00 amRNSNotice of Results & Investor Presentation
31st Mar 20267:00 amRNSTrading and Operational Update
19th Mar 20267:00 amRNSInterim Dividend and Dividend Declaration
26th Jan 20267:00 amRNSDirector/PDMR Shareholding
22nd Dec 20257:00 amRNSFollow-On Investment into Tristone Healthcare Ltd
22nd Dec 20257:00 amRNSFollow-On Investment into Tristone Healthcare Ltd
18th Dec 20257:00 amRNSInterim Dividend and Dividend Declaration
4th Dec 20257:00 amRNSInterim Financial Results
17th Oct 20257:00 amRNSFollow-On Investment into Step Investments Limited
1st Oct 20257:00 amRNSFollow-On Investment into Integrum Group Holdings
29th Sep 20257:00 amRNSTrading Update
18th Sep 20257:00 amRNSInterim Dividend and Dividend Declaration
4th Aug 202511:17 amRNSResult of Annual General Meeting
1st Aug 20258:08 amRNSDirector/PDMR Dealings
11th Jul 20257:00 amRNSAnnual Report & Notice of Annual General Meeting
25th Jun 20257:00 amRNSFinal Results for the year ended 31 March 2025
19th Jun 20257:00 amRNSInterim Dividend and Dividend Declaration
2nd Jun 20257:00 amRNSFollow-On Investment into Existing Capital Partner
27th May 20257:00 amRNSNotice of Results & Investor Presentation
2nd Apr 20257:00 amRNSFollow-On Investment into Existing Capital Partner
31st Mar 20257:00 amRNSTrading and Operational Update
20th Mar 20257:00 amRNSInterim Dividend and Dividend Declaration
19th Feb 20257:00 amRNSFollow-On Investment into BPVA (Ireland) Limited
30th Dec 20247:00 amRNSTrading and Operational Update
17th Dec 202412:50 pmRNSInterim Dividend and Dividend Declaration
16th Dec 20247:00 amRNSInterim Results for the six months ended 30 Sep 24
4th Dec 20249:40 amRNSDirector/PDMR Shareholding
3rd Dec 202411:34 amRNSResult of General Meeting and Issue of Equity
22nd Nov 20243:38 pmRNSResult of Retail Offer and Broker Option
15th Nov 20247:00 amRNSResult of Placing
14th Nov 20245:02 pmRNSRetail Offer to raise up to £3.0 million
14th Nov 20245:01 pmRNSIssue of Equity
30th Sep 20247:00 amRNSTrading and Operational Update
19th Sep 20247:00 amRNSInterim Dividend and Dividend Declaration
3rd Sep 20247:00 amRNSFollow-On Investment into United Glass Group
1st Aug 20243:16 pmRNSDirector/PDMR Dealings
1st Aug 202411:40 amRNSResult of Annual General Meeting
22nd Jul 20247:00 amRNSFollow-On Investment into Step Investments Limited
15th Jul 20247:00 amRNSAnnual Report & Notice of Annual General Meeting
27th Jun 20247:00 amRNSFinal Results for the year ended 31 March 2024
20th Jun 202411:50 amRNSInterim Dividend and Dividend Declaration
3rd Jun 20247:00 amRNSNotice of Results
17th May 202411:45 amEQSHardman & Co Q&A on Duke Capital (DUKE) | Generating investor returns by uniquely meeting customer needs
3rd May 20247:00 amRNSFollow-On Investment into Existing Capital Partner
29th Apr 20242:45 pmEQSHardman & Co Research Initiation of Coverage on Duke Capital (DUKE): Meeting customer needs, giving investors returns
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.